ArticleBMJ global health2025
Eight-year tuberculosis epidemic trends in the Republic of Congo, a high TB burden country: progress and gaps towards end-TB targets.
Article in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- National Implementation of a Tuberculosis Sample Referral Network to Expand Access to Molecular Diagnosis in the Republic of Congo: Pilot Evaluation and Programmatic Analysis (2023-2025).Tropical medicine and infectious disease · 2026Article
- Article
- Anti-tuberculosis drug-induced hepatotoxicity among patients undergoing tuberculosis treatment at the Antituberculosis Center of Brazzaville, Republic of Congo.IJID regions · 2026Article
- Patient-related diagnostic delay and risk of unfavorable treatment outcomes among pulmonary tuberculosis patients at the antituberculosis center of Brazzaville, Republic of Congo.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvaluating progress towards WHO End Tuberculosis Strategy goals is crucial for high burden countries like the Republic of Congo. This study analysed trends in tuberculosis (TB) incidence, treatment, care quality and operational research activities from 2016 to 2023 to assess the country's control efforts.
methodsAn 8-year retrospective study of TB incidence/mortality trends was performed using a Joint Point Analysis V.5.2.0. We extracted annual national and WHO TB programme data for the period under review.
resultsFrom 2016 to 2023, the TB incidence rate decreased by 2.6% (annual percentage change (APC)=-0.33, 95% CI- 0.5 to -0.005; p<0.05). The proportion of bacteriologically confirmed cases significantly increased (APC=4.2, 95% CI 0.9 to 7.7; p<0.001), while treatment coverage rose by 22% (APC=2.81, 95% CI 1.1 to 4.5; p<0.05). The proportion of notified patients with TB tested for HIV significantly increased (APC=25, 95% CI 2.6 to 52.63; p<0.05), but the rate of patients with TB testing HIV positive decreased significantly (APC=-13.9, 95% CI -23.9 to -2.6; p<0.05). The proportion of unsuccessful treatment outcomes showed a non-significant decline, with an APC of 4.90% (95% CI -11.7% to 2.3%; p=0.1), while TB-related deaths increased non-significantly, with an APC of 3.76% (95% CI -1.3% to 9.2%; p=0.12). Patients with TB/HIV on ART increased by 51% (APC=6.4, 95% CI -23.9 to -2.6; p<0.05). No operational research activity has been carried out throughout the review period.
conclusionThe observed progress was insufficient, as the Republic of Congo failed to meet the 20% TB incidence reduction target for 2020 and is unlikely to achieve the 50% reduction goal for 2025. More investment in case detection, diagnosis, treatment quality and the implementation of operational research activities is needed to achieve global goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.